-
Atea Pharmaceuticals NASDAQ:AVIR Atea is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing therapies to address the unmet medical needs of patients with life-threatening viral diseases. Leveraging its deep understanding of antiviral drug development, nucleoside biology, and medicinal chemistry, the Company has built a proprietary purine nucleotide prodrug platform to develop novel product candidates to treat single stranded ribonucleic acid, or ssRNA, viruses, which are a prevalent cause of severe viral diseases. Currently, the Company is focused on the development of orally available, potent, and selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19, dengue virus, hepatitis C virus (HCV) infection, and respiratory syncytial virus (RSV).
Location: | Website: ateapharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
-218.2M
Cash
502.2M
Avg Qtr Burn
-30.37M
Short % of Float
4.31%
Insider Ownership
9.68%
Institutional Own.
69.80%
Qtr Updated
06/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Bemnifosbuvir + Ruzasvir (RZR) Details Hepatitis C | Phase 2 Data readout | |
Failed Discontinued | ||
AT-527 (Bemnifosbuvir) Details COVID-19, Infectious disease | Failed Discontinued | |
AT-752 Details Infectious disease, Dengue Fever | Failed Discontinued |